SCHEMBL4848229

SCHEMBL4848229

CON(C)C(=O)c1cc2cnc(SC)nc2n1-c1ccc(F)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
PDE4B Q07343 1/20 0.33
CDK4 P11802 5/20 0.33
CCNT1 O60563 1/20 0.33
CCND3 P30281 1/20 0.33
CDK9 P50750 1/20 0.33
RXFP1 Q9HBX9 2/20 0.32
TRPM8 Q7Z2W7 1/20 0.32
PIK3CD O00329 1/20 0.32
PIK3CA P42336 1/20 0.32
MTOR P42345 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
TSHR P16473 1/20 0.32
GRM5 P41594 1/20 0.31
HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4855162 0.87 PIK3CD (0.40) MAPTSMN1; SMN2ALDH1A1LMNAGAA
SCHEMBL4852894 0.83 NOTUM (0.39) MAPTSMN1; SMN2ALDH1A1LMNAGAA
SCHEMBL14163858 0.82 CDK4 (0.33) MAPTSMN1; SMN2ALDH1A1LMNAGAA
SCHEMBL4850875 0.82 MAPT (0.38) MAPTSMN1; SMN2ALDH1A1LMNAGAA
SCHEMBL14158805 0.80 MAPK1 (0.46) MAPTSMN1; SMN2ALDH1A1LMNAMAPK1
SCHEMBL4848223 0.80 RXFP1 (0.39) MAPTLMNAPDE4BRXFP1MAPK1
SCHEMBL14280497 0.79 MAPT (0.34) MAPTSMN1; SMN2ALDH1A1LMNAGAA
SCHEMBL14158831 0.74 MAPT (0.55) MAPTLMNACDK4RXFP1
SCHEMBL4856292 0.73 MAPT (0.38) MAPTSMN1; SMN2LMNARXFP1MAPK1
SCHEMBL14248954 0.73 GRM5 (0.34) MAPTSMN1; SMN2ALDH1A1TRPM8PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080139588-A1 Pyrrolo[2,3-d]pyrimidine cytokine inhibitors THE PROCTER & GAMBLE COMPANY 2008-06-12 US disclosed
US-20080139588-A1 Pyrrolo[2,3-d]pyrimidine cytokine inhibitors THE PROCTER & GAMBLE COMPANY 2008-06-12 US disclosed
US-7319102-B1 Pyrrolo[2,3-d]pyrimidine cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-01-15 US disclosed
US-7319102-B1 Pyrrolo[2,3-d]pyrimidine cytokine inhibitors THE PROCTER & GAMBLE COMPANY (US) 2008-01-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139588-A1 Pyrrolo[2,3-d]pyrimidine cytokine inhibitors DPYD, IL1B, IL6 MAPT 3310/4885SMN1; SMN2 4002/4885ALDH1A1 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.